Profil
Eric M.
Sullivan currently works at Chimeric Therapeutics Ltd. (Australia), as Non-Executive Director from 2023 and Convergent Therapeutics, Inc., as Chief Financial Officer from 2023.
Mr. Sullivan also formerly worked at bluebird bio, Inc., as Chief Accounting Officer, VP-Finance & Treasurer from 2016 to 2017, TCR2 Therapeutics, Inc., as Chief Financial Officer, Triplet Therapeutics, Inc., as President, Chief Operating & Financial Officer, and Gemini Therapeutics, Inc., as Senior Vice President.
Mr. Sullivan received his undergraduate degree from Bentley University.
Postes actifs de Eric Sullivan
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 30/08/2023 |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Directeur Financier/CFO | 01/09/2023 |
Anciens postes connus de Eric Sullivan
| Sociétés | Poste | Fin |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Comptroller/Controller/Auditor | 04/08/2017 |
| GEMI THER | Corporate Officer/Principal | - |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | President | - |
| TCR2 THERAPEUTICS INC. | Directeur Financier/CFO | - |
Formation de Eric Sullivan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Bentley University
Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | Health Services |
Chimeric Therapeutics Ltd. (Australia)
Chimeric Therapeutics Ltd. (Australia) BiotechnologyHealth Technology Develops cell therapies for the tumors | Health Technology |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Health Technology |
















